March 12, 2018 / 10:43 AM / 3 months ago

BRIEF-Merrimack Provides Business Update And Reports 2017 Financial Results

March 12 (Reuters) - Merrimack Pharmaceuticals Inc:

* MERRIMACK PROVIDES BUSINESS UPDATE AND REPORTS 2017 FINANCIAL RESULTS

* ‍EXPECTS THREE CLINICAL READOUTS IN 2018, INCLUDING DATA FROM TWO RANDOMIZED PHASE 2 STUDIES​

* ‍ANNOUNCED FORMATION OF A NEW SCIENTIFIC ADVISORY BOARD WITH EXPERTISE IN PRECISION ONCOLOGY​

* MERRIMACK PHARMACEUTICALS -‍ CLOSURE OF 2017 WITH $93.4 MILLION IN CASH, CASH EQUIVALENTS, EXTINGUISHMENT OF $60.8 MILLION OF CONVERTIBLE DEBT IN Q4​

* MERRIMACK PHARMACEUTICALS - CONTINUES TO BELIEVE THAT CASH & CASH EQUIVALENTS AS OF DEC 31, 2017 WILL BE SUFFICIENT TO FUND PLANNED OPERATIONS INTO H2 2019

* Q4 LOSS PER SHARE $0.89 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below